By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


PeriCor Therapeutics 

350 Fifth Avenue
59th Floor
New York  New York  10118  U.S.A.
Phone: 212-601-2725 Fax: 212-601-2726


Company News
PeriCor Therapeutics Reports Positive Preclinical Results of GP531 at the European Heart Failure Congress in Nice 6/3/2009 8:37:18 AM
PeriCor Therapeutics Appoints K. Tucker Andersen to Board of Directors 2/13/2008 7:12:11 AM
PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation (SGP) 8/20/2007 11:40:08 AM
PeriCor Therapeutics Appoints Larry G. Pickering To Board Of Directors 12/6/2006 10:18:55 AM
PeriCor Therapeutics Mourns The Loss Of Ross Dixon, Ph.D., Vice President, Pharmaceutical Development 12/4/2006 2:22:38 PM
PeriCor Therapeutics Elects Robert L. Engler, M.D. To Board Of Directors 7/6/2006 2:23:43 PM
PeriCor Therapeutics Release: Acadesine Reduces Two-Year Mortality Following Heart Attacks In Heart Bypass Patients 5/12/2006 11:11:42 AM
PeriCor Therapeutics Reports Positive Two-Year Mortality Results Of Acadesine At The American College of Cardiology's Scientific Session 3/14/2006 2:30:20 PM